Górski Andrzej, Borysowski Jan, Międzybrodzki Ryszard
Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), 53-114 Wrocław, Poland.
Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), 53-114 Wrocław, Poland.
Pathogens. 2020 Oct 15;9(10):844. doi: 10.3390/pathogens9100844.
Phage therapy has emerged as a potential novel treatment of sepsis for which no decisive progress has been achieved thus far. Obviously, phages can help eradicate local bacterial infection and bacteremia that may occur in a syndrome. For example, phages may be helpful in correcting excessive inflammatory responses and aberrant immunity that occur in sepsis. Data from animal studies strongly suggest that phages may indeed be an efficient means of therapy for experimentally induced sepsis. In recent years, a number of reports have appeared describing the successful treatment of patients with sepsis. Moreover, novel data on the anti-viral potential of phages may be interpreted as suggesting that phages could be used as an adjunct therapy in severe COVID-19. Thus, clinical trials assessing the value of phage therapy in sepsis, including viral sepsis, are urgently needed.
噬菌体疗法已成为脓毒症一种潜在的新型治疗方法,而迄今为止尚未取得决定性进展。显然,噬菌体有助于根除局部细菌感染以及综合征中可能出现的菌血症。例如,噬菌体可能有助于纠正脓毒症中出现的过度炎症反应和异常免疫。动物研究数据有力地表明,噬菌体确实可能是治疗实验性脓毒症的有效手段。近年来,出现了一些报告描述脓毒症患者的成功治疗。此外,关于噬菌体抗病毒潜力的新数据可解释为表明噬菌体可作为重症COVID-19的辅助治疗。因此,迫切需要进行临床试验以评估噬菌体疗法在脓毒症(包括病毒性脓毒症)中的价值。